share_log

BTIG Initiates Coverage On ProMIS Neurosciences With Buy Rating, Announces Price Target of $8

Benzinga ·  Oct 3, 2023 04:43

BTIG analyst Thomas Shrader initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment